These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27591073)

  • 21. Pramipexole extended release in Parkinson's disease.
    Hametner EM; Seppi K; Poewe W
    Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
    Nodel' MR; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):32-8. PubMed ID: 18577955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in body weight after pramipexole treatment in Parkinson's disease.
    Kumru H; Santamaria J; Valldeoriola F; Marti MJ; Tolosa E
    Mov Disord; 2006 Nov; 21(11):1972-4. PubMed ID: 16972276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correspondence: The pathophysiology of pramipexole-associated dystonia in patients with Parkinson's disease.
    Park D
    Parkinsonism Relat Disord; 2017 May; 38():106-107. PubMed ID: 28291593
    [No Abstract]   [Full Text] [Related]  

  • 27. Pramipexole for the treatment of early Parkinson's disease.
    Perez-Lloret S; Rey MV; Ratti L; Rascol O
    Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
    Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
    Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K;
    Mov Disord; 2011 Jan; 26(1):37-44. PubMed ID: 20925067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sleep episodes in Parkinson's disease: a wake-up call.
    Frucht SJ; Greene PE; Fahn S
    Mov Disord; 2000 Jul; 15(4):601-3. PubMed ID: 10928569
    [No Abstract]   [Full Text] [Related]  

  • 32. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable frequency stimulation of subthalamic nucleus for freezing of gait in Parkinson's disease.
    Jia F; Guo Y; Wan S; Chen H; Hao H; Zhang J; Li L
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1471-2. PubMed ID: 26467485
    [No Abstract]   [Full Text] [Related]  

  • 34. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 35. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 36. Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease.
    Davis JL; Kurek JA; Morgan JC; Sethi KD
    Neurology; 2018 Jan; 90(3):e263. PubMed ID: 29335315
    [No Abstract]   [Full Text] [Related]  

  • 37. Pramipexole: heart failure.
    Prescrire Int; 2013 Sep; 22(141):213. PubMed ID: 24171217
    [No Abstract]   [Full Text] [Related]  

  • 38. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of dystonia in Parkinson's disease.
    Tsui JK
    Adv Neurol; 2003; 91():361-4. PubMed ID: 12442694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.